BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes 2020;4:14. [PMID: 32076853 DOI: 10.1186/s41687-020-0179-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lodise T, Rodriguez M, Chitra S, Wright K, Patel N. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective. Antibiotics (Basel) 2021;10:1195. [PMID: 34680776 DOI: 10.3390/antibiotics10101195] [Reference Citation Analysis]
2 Khanna S. My Treatment Approach to Clostridioides difficile Infection. Mayo Clin Proc 2021;96:2192-204. [PMID: 34175104 DOI: 10.1016/j.mayocp.2021.03.033] [Reference Citation Analysis]
3 Mehta SR, Yen EF. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy. Transl Res 2021;230:197-207. [PMID: 33278650 DOI: 10.1016/j.trsl.2020.11.013] [Reference Citation Analysis]
4 Hammeken LH, Baunwall SMD, Dahlerup JF, Hvas CL, Ehlers LH. Health-related quality of life in patients with recurrent Clostridioides difficile infections. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078441] [Reference Citation Analysis]